Arbutus Biopharma Corp (ABUS)

2.880 0.000 (0.00%)
Closed USD Disclaimer
2.900 +0.020 (+0.694%)

Arbutus Biopharma Corp Company Profile

Equity Type
Arbutus Biopharma Corporation is a clinical-stage, biopharmaceutical company. The Company is focused on virology capabilities to develop therapeutics that target specific viral diseases. The Company’s focus areas include Hepatitis B virus (HBV), SARS-CoV-2 and other coronaviruses. In HBV, the Company is developing a ribonucleic acid interference (RNAi) therapeutic, an oral capsid inhibitor, an oral programmed death-ligand-1 (PD-L1) inhibitor, and an oral RNA destabilizer that it intends to combine to provide a functional cure for patients with chronic HBV infection (cHBV) by suppressing viral replication, reducing surface antigen and reawakening the immune system. Its lead compound, AB-729, is the only RNAi therapeutic with evidence of immune re-awakening and is being evaluated in multiple Phase II clinical trials. The Company is also having an ongoing drug discovery and development program directed at identifying orally active agents for treating coronaviruses, including SARS-CoV-2.
Contact Information
Warminster,18974 United States
267 469 0914
267 282 0411
Top Executives
Frank M. Torti 42 2018 Independent Chairman of the Board of Directors
William T. Symonds 56 2015 Chairman of Scientific Advisory Board
Daniel D. Burgess 62 2017 Independent Director
Fabien Zoulim 0 0000 Member of Scientific Advisory Board
Richard C. Henriques 68 2014 Independent Non-Executive Director
Charles M. Rice 0 0000 Member of Scientific Advisory Board
Scott A. Biller 68 0000 Member of Scientific Advisory Board
Kyong-Mi Chang 0 0000 Member of Scientific Advisory Board
James R. Meyers 59 2018 Independent Director
Adrian Di Bisceglie 0 0000 Member of Scientific Advisory Board
Melissa V. Rewolinski 53 2023 Independent Director
Ulrike Protzer 0 0000 Member of Scientific Advisory Board
Clear All
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.